Follow-up survey of Japanese medical students’ interactions with the pharmaceutical industry by 前野 貴美 et al.
Follow-up survey of Japanese medical students
’ interactions with the pharmaceutical
industry
著者（英） Sayaka Saito, Takami MAENO, Yasushi Miyata,
Tetsuhiro Maeno
journal or
publication title
PLOS ONE
volume 13
number 11
page range e0206543
year 2018-11
権利 (C)2018Saitoet al. This is an
openaccessarticledistributedunderthe termsof
theCreativeCommonsAttributionLicense,whichperm
itsunrestricted use, distribution,
andreproductionin any medium,providedthe
originalauthorand sourceare credited.
URL http://hdl.handle.net/2241/00154701
doi: 10.1371/journal.pone.0206543
Creative Commons : 表示
http://creativecommons.org/licenses/by/3.0/deed.ja
RESEARCH ARTICLE
Follow-up survey of Japanese medical
students’ interactions with the
pharmaceutical industry
Sayaka SaitoID1, Takami Maeno1*, Yasushi Miyata2, Tetsuhiro Maeno1
1 Department of Primary Care and Medical Education, University of Tsukuba, Tsukuba, Ibaraki, Japan,
2 Department of Primary Care and Community Health, Medical Education Center, Aichi Medical University
School of Medicine, Nagakute, Aichi, Japan
* takami-m@md.tsukuba.ac.jp
Abstract
Interaction of medical students with the pharmaceutical industry is common. However,
students are thought to be vulnerable to the influence of this interaction, and regulations
to limit such interactions are required. The Japan Pharmaceutical Manufacturers Associa-
tion revised its promotion code in 2013 and specified upper limits for promotional aids. We
aimed to investigate whether Japanese medical students’ interactions with the pharmaceuti-
cal industry changed from 2012 to 2016. This study solicited the participation of all medical
schools in Japan. An anonymous cross-sectional survey was administered to medical
students from May 2016 to March 2017 to investigate their interactions with the pharmaceu-
tical industry. The results were compared with those of a previous study conducted in 2012.
Forty of the 80 medical schools in Japan participated. The student response rate was
74.1%, with 6771 (3395 preclinical, 3376 clinical) evaluable responses. More than 98% of
clinical students had previously accepted stationery, a brochure, or a lunch, and significantly
higher percentages of clinical students had accepted these items in 2016 than in 2012 (p <
.001). The interactions between clinical students and pharmaceutical companies increased
slightly between 2012 and 2016. This study will hopefully promote discussion regarding the
regulation of student–industry interactions.
Introduction
Studies in many countries have shown that the pharmaceutical industry frequently interacts
not only with physicians, but also with medical students [1–5]. The physician–industry rela-
tionship can lead to lower prescribing quality [6,7]. Trainees and students are thought to also
be vulnerable to the influence of the pharmaceutical industry, and regulations to limit interac-
tions between students and the industry are required [8,9].
Attempts to reduce industry influence include both government regulation and self-regula-
tion [10]. An example of government regulation is the Physician Payment Sunshine Act, pro-
posed in 2009 in the United States to require pharmaceutical companies to disclose payments
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and gifts to physicians [11]. In Finland, legislative reform passed in 2004 instituted fines for
both physicians and the pharmaceutical industry in cases where gifts have more than a modest
monetary value and where gifts or events have no educational value [12]. However, in Japan,
there are no laws regulating or requiring disclosure of the relationship between physicians and
the pharmaceutical industry.
Self-regulatory measures have been published by both the pharmaceutical industry and
professional medical organizations in the United States. In 2008, the American Medical Asso-
ciation and the American College of Physicians released stringent ethical codes, and the Asso-
ciation of American Medical Colleges released a task force report calling on academic health
centers to develop rules regarding interactions with the industry in the same year [8]. The
Institute of Medicine has also released a recommendation report on conflicts of interest [13],
and the Pharmaceutical Research and Manufacturers of America revised their promotion code
in 2009 [14]. Only a few studies have followed up the frequency of interactions between medi-
cal students and the pharmaceutical industry as a result of these changes [5,12]. One follow-up
survey in the United States reported that the number of interactions of any kind between med-
ical students and the pharmaceutical industry decreased from 4.1 per month in 2003 to 1.6 per
month in 2012, and the percentage of medical students who received any gifts from industry
representatives decreased from 100% to 79% over the same period [5].
In Japan, professional societies have not published recommendations or restrictions on
the physician–industry relationship, although a 2008 recommendation by the Association of
American Medical Colleges being translated into Japanese in 2012. The Japan Pharmaceutical
Manufacturers Association (JPMA) revised its promotion code in 2013 to meet the Interna-
tional Federation of Pharmaceutical Manufacturers & Associations’ Code of Practices, revised
in 2012, which specified that promotional aids should cost 3,000 yen (approximately US$30)
or less and that items of medical utility provided to physicians should be less than 3,000 to
5,000 yen (approximately US$30 to US$50) in value [15]. A national survey of Japanese medi-
cal students conducted in 2012 reported that 98% of clinical students had received stationery
such as pens and notepads and that 97% had received a lunch at a promotional meeting for
pharmaceutical industry products [16]. However, the interactions of Japanese medical stu-
dents with the pharmaceutical industry have not been evaluated since 2012.
We aimed to examine whether there were any changes in Japanese medical students’ inter-
actions with the pharmaceutical industry between 2012 and 2016.
Methods
The questionnaires administered to students were part of a larger, anonymous, self-adminis-
tered survey investigating medical students’ interactions with and attitudes toward the phar-
maceutical industry. The institutional review board at Tsukuba University approved the
survey protocol, including use of data from the 2012 survey.
Participants
For the 2012 survey, participating schools were non-randomly chosen based on access to fac-
ulty members who could administer the survey at each school. Each school independently
decided which student cohort years would participate in the survey. The researchers did not
specify the distribution methods or target cohort years when sending a set of questionnaire to
each school. The researchers were informed about whether participants were preclinical or
clinical by each school.
For the 2016 survey, we sent forms requesting study participation to the Deans of all 80
medical schools in Japan from April to May 2016. Preclinical and clinical students in medical
Medical student–pharmaceutical industry interaction
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schools whose Deans approved study participation were invited. In general, medical students
receive education for 6 years in Japan: They complete general liberal arts classes in the first 2
years, lectures on basic medicine in the next 2 years, and clinical practical training in the last 2
years. We asked the person in charge of administering the survey at each school to administer
the survey to both preclinical and clinical students, if possible. We asked them to select a
cohort year for preclinical students, according to feasibility, among students who had not yet
begun their clinical clerkship programs at the time of the survey. We specified that first to
third year students were favorable. Clinical students in Japan are in their fifth and sixth years
of medical school. The 11-month investigation period ran from the beginning of a school year
to the end of a school year. Thus, the inclusion of fifth-year students in the study would have
meant that some participants had just started their clinical training, whereas others had experi-
enced clinical training for almost 1 year. We assumed that including students with more clini-
cal training would better demonstrate the impact of clinical training on the degree of exposure
to the pharmaceutical industry. Therefore, we included only sixth-year clinical students, as
these students had all experienced one year of clinical training. We confirmed the cohort years
of preclinical students and the sizes of the selected classes before sending a set of question-
naires to each school.
Survey instrument
The cover page of the questionnaire stated the purpose of the study and confirmed the volun-
tary nature of participation, as well as the confidentiality of responses. No incentives were
offered for participation. The survey questions asked whether participants had ever accepted
one or more of four items (stationery, a medical textbook, a brochure, or a lunch), and some
additional questions that were asked in the 2012 survey were also included [16]. The question-
naire was not pretested for validity and reliability before being administered in the study.
Survey administration
From May 2016 to March 2017, we sent a set of questionnaires to a staff or faculty member at
each participating school, as determined by that institution’s Dean. Paper questionnaires were
distributed and filled out with pens in a class with required attendance and collected on the
same occasion. Completed questionnaires were returned by mail.
Analysis
Descriptive statistics were computed for all variables. We used Pearson chi-square tests to
compare the responses on accepting the four items in the 2012 and 2016 surveys. Two-tailed
p-values less than .05 were considered to indicate statistical significance. SPSS, Version 23.0
was used for all statistical analyses.
Results
Participant characteristics
In the 2012 survey, 43 of the 80 medical schools in Japan participated. A total of 24 schools
were national, 5 were prefectural, and 14 were private. Forty medical schools (50%) partici-
pated in the 2016 study. Of these, 22 were national, 6 were prefectural, and 12 were private.
Twenty-two schools participated in the survey in both 2012 and 2016. Of the 9132 students in
the surveyed classes, there were 6771 evaluable responses, making the overall response rate
74.1%, which exceeded the 60% generally considered necessary for a survey to be valid. The
response rate was 72.8% (3395/4661) among preclinical students and 75.5% (3376/4471)
Medical student–pharmaceutical industry interaction
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among clinical students. Cronbach’s alpha was 0.83 for the 2012 survey and 0.85 for the 2016
survey. Table 1 shows the demographic characteristics of the survey participants in both 2012
and 2016. In the 2012 survey, where the cohort years of participating students were decided at
each school according to feasibility, there were no first- to third-year preclinical students, two-
thirds of the participants were in their fourth year, and the remaining one-third were in their
fifth year. In the 2016 survey, first-, second-, and third-year students accounted for 21%, 32%,
and 44% of the preclinical students, respectively. Regarding clinical students, there were
approximately equal numbers of fifth- and sixth-year students in the 2012 survey; in the 2016
survey, clinical students were defined as being in their sixth year.
Comparison between 2012 and 2016
In both 2012 and 2016, one in three preclinical students reported having accepted stationery
from the pharmaceutical industry (36.8% and 30.4%, respectively; p< .001). More preclinical
students in 2012 than in 2016 reported having accepted a brochure (31.2% vs. 17.6%, respec-
tively; p< .001) or a lunch (21.2% vs. 13.0%, respectively; p< .001), whereas fewer preclinical
students reported having accepted a textbook in 2012 than in 2016 (4.1% vs. 5.3%, respectively;
p = .03).
Comparing the clinical students’ responses in 2012 and 2016, 97.1% and 98.3% (p = .001)
had accepted stationery, 97.4% and 98.6% (p = .001) had accepted a brochure, and 96.6% and
98.8% (p = .001) had accepted a lunch, respectively. Ten percent more students had received a
textbook in 2016 than in 2012 (26.7% vs. 16.9%, respectively; p< .001) (Table 2).
Discussion
This was a follow-up to a study conducted in 2012, which evaluated Japanese medical students’
interactions with the pharmaceutical industry. Most of the clinical students reported having
accepted stationery, a brochure, and a lunch in both 2012 and 2016. The higher rate at which
clinical students interacted with the pharmaceutical industry, compared with preclinical stu-
dents, was similar to the pattern seen among Japanese physicians in a previous survey in 2008,
in which 96% of respondents reported receiving stationery [17].
Table 1. Characteristics of respondents.
Pre-clinical Clinical
2012 2016 2012 2016
n = 2660 n = 3395 n = 2672 n = 3376
n (%) n (%) n (%) n (%)
Year of study
1st 0 (0) 705 (20.8) 0 (0) 0 (0)
2nd 0 (0) 1101 (32.4) 0 (0) 0 (0)
3rd 0 (0) 1479 (43.6) 0 (0) 0 (0)
4th 1755 (66.0) 110 (3.2) 0 (0) 0 (0)
5th 853 (32.1) 0 (0) 1369 (51.2) 0 (0)
6th 53 (2.0) 0 (0) 1303 (48.8) 3376 (100)
Ownership of schools
National 1496 (56.2) 1756 (51.7) 1728 (64.7) 1819 (53.9)
Prefectural 326 (12.3) 438 (12.9) 173 (6.5) 364 (10.8)
Private 838 (31.5) 1201 (35.4) 771 (28.9) 1193 (35.3)
https://doi.org/10.1371/journal.pone.0206543.t001
Medical student–pharmaceutical industry interaction
PLOS ONE | https://doi.org/10.1371/journal.pone.0206543 November 2, 2018 4 / 7
The degree of interaction between clinical students and the pharmaceutical industry
increased slightly but significantly from 2012 to 2016. In particular, approximately 10% more
students reported having accepted a textbook in 2016 than in 2012. This increase was observed
despite a 2008 recommendation by the Association of American Medical Colleges being trans-
lated into Japanese in 2012 and the JPMA’s 2013 release of the revised Code of Practice [15],
which was expected to restrict medical students’ and physicians’ interactions with the industry.
One year after the 2008 revision of the ethics codes of academic societies in the United States,
there was a decrease in the number of student interactions with the pharmaceutical industry
[5]. A follow-up survey of the relationships between physicians and the industry in the United
States showed a reduction in their interactions from 2004 to 2009, despite the lack of regula-
tions banning gifts and meetings with pharmaceutical representatives [18]. The authors of this
previous study considered the reasons for this decrease to be increased attention to the propri-
ety of physician–industry interactions by the press and professional organizations, increased
public reporting of these interactions, new institutional policies, and company cutbacks on
marketing expenses. The current survey was administered 3 years after the revision of the
promotion code by the JPMA, which set an upper limit on gifts. It seems natural that the inter-
action was not found to decrease, because the monetary values of the types of interaction
examined in the present survey were below the upper limit set by the code. However, we
would expect the code to change the marketing strategies of the industry, as well as institu-
tional policies, which could decrease the interaction [18]. Actually, however, our findings
indicate that the latest revision of the code did not decrease the interaction between clinical
students and the pharmaceutical industry, and other regulation such as self-regulation by
professional societies is probably required to decrease medical students’ interaction with the
industry. Although preclinical students’ interactions with the pharmaceutical industry did
decrease, this may have been because of a greater number of lower-year participants in 2016
than in 2012.
This study had several limitations. First, only half of all medical schools in Japan partici-
pated in the study, raising concerns about participation bias. Many schools declined to partici-
pate because of the survey content, and others may have had negative viewpoints regarding
educating students about the relationship with the pharmaceutical industry. Second, the
recruitment method differed between 2016 and 2012: In 2012, schools were non-randomly
chosen based on access to faculty members who could administer the survey at each school.
Thus, a simple comparison between the 2012 and 2016 results may not reflect actual changes.
Third, the respondents may have reported socially desirable responses despite the provision of
Table 2. Interaction between medical students and the pharmaceutical industry ‡�.
Pre-clinical Clinical
2012
(n = 2660)
2016
(n = 3395)
Comparison of proportions,
2012 versus 2016†
2012
(n = 2672)
2016
(n = 3376)
Comparison of proportions,
2012 versus 2016†
Type of gift or event n % N % p value n % n % p value
Stationery 980 36.8 1031 30.4 < .001 2594 97.1 3318 98.3 0.001
Medical textbook 110 4.1 181 5.3 0.03 452 16.9 901 26.7 < .001
Brochure 831 31.2 598 17.6 < .001 2602 97.4 3328 98.6 0.001
Lunch provided at a promotional presentation 563 21.2 440 13.0 < .001 2581 96.6 3332 98.8 < .001
‡ Sample sizes varied by item because of nonresponse. The percentages of nonresponse were less than 0.18%.
� Percentages for all items were significantly higher among clinical students than among preclinical students (chi-square test, p < .001).
† Chi-square test
https://doi.org/10.1371/journal.pone.0206543.t002
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anonymity and the survey being self-administered; this might have led to an underestimation
of their industry interactions.
In the future, it is expected that professional societies will formulate guidelines on relation-
ships between physicians or medical students and the pharmaceutical industry. Interactions
between medical students and the pharmaceutical industry need to be closely monitored after
regulations come into effect.
In conclusion, this study revealed that students’ interactions with the pharmaceutical indus-
try barely changed between the 2012 and 2016 surveys, and these interactions were not influ-
enced by the revised promotion code. Discussions about the regulation of the relationship
with the pharmaceutical industry are required in the field of medical education.
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